Ascentage Pharma Group International
Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company's primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibit… Read more
Ascentage Pharma Group International (AAPG) - Net Assets
Latest net assets as of June 2025: $675.91 Million USD
Based on the latest financial reports, Ascentage Pharma Group International (AAPG) has net assets worth $675.91 Million USD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($3.05 Billion) and total liabilities ($2.37 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $675.91 Million |
| % of Total Assets | 22.19% |
| Annual Growth Rate | N/A |
| 5-Year Change | -67.62% |
| 10-Year Change | N/A |
| Growth Volatility | 134.19 |
Ascentage Pharma Group International - Net Assets Trend (2016–2024)
This chart illustrates how Ascentage Pharma Group International's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Ascentage Pharma Group International (2016–2024)
The table below shows the annual net assets of Ascentage Pharma Group International from 2016 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $274.16 Million | +288.16% |
| 2023-12-31 | $70.63 Million | -82.72% |
| 2022-12-31 | $408.66 Million | -66.90% |
| 2021-12-31 | $1.23 Billion | +45.84% |
| 2020-12-31 | $846.62 Million | -4.92% |
| 2019-12-31 | $890.48 Million | +188.03% |
| 2018-12-31 | $-1.01 Billion | -667.53% |
| 2017-12-31 | $-131.80 Million | -802.35% |
| 2016-12-31 | $-14.61 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Ascentage Pharma Group International's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 577055500000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $214.00K | 0.08% |
| Other Comprehensive Income | $-510.59 Million | -193.26% |
| Other Components | $6.55 Billion | 2477.39% |
| Total Equity | $264.19 Million | 100.00% |
Ascentage Pharma Group International Competitors by Market Cap
The table below lists competitors of Ascentage Pharma Group International ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Inner Mongolia MengDian HuaNeng Thermal Power Corp Ltd
SHG:600863
|
$2.25 Billion |
|
TISCO Financial Group Public Company Limited
BK:TISCO
|
$2.25 Billion |
|
Lineage, Inc. Common Stock
NASDAQ:LINE
|
$2.25 Billion |
|
SPS Commerce Inc
NASDAQ:SPSC
|
$2.25 Billion |
|
MiTAC Holdings Corp
TW:3706
|
$2.25 Billion |
|
Zai Lab Ltd
NASDAQ:ZLAB
|
$2.24 Billion |
|
COFCO Tunhe Sugar Co Ltd
SHG:600737
|
$2.24 Billion |
|
TRIPLE FLAG PREC.MET.
F:3Y0
|
$2.24 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Ascentage Pharma Group International's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 60,417,000 to 264,194,000, a change of 203,777,000 (337.3%).
- Net loss of 405,433,000 reduced equity.
- New share issuances of 533,940,000 increased equity.
- Other comprehensive income decreased equity by 6,125,000.
- Other factors increased equity by 81,395,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-405.43 Million | -153.46% |
| Share Issuances | $533.94 Million | +202.1% |
| Other Comprehensive Income | $-6.12 Million | -2.32% |
| Other Changes | $81.39 Million | +30.81% |
| Total Change | $- | 337.28% |
Book Value vs Market Value Analysis
This analysis compares Ascentage Pharma Group International's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 27.90x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | $-0.28 | $24.40 | x |
| 2017-12-31 | $-2.55 | $24.40 | x |
| 2018-12-31 | $-19.54 | $24.40 | x |
| 2019-12-31 | $16.84 | $24.40 | x |
| 2020-12-31 | $15.68 | $24.40 | x |
| 2021-12-31 | $19.40 | $24.40 | x |
| 2022-12-31 | $6.20 | $24.40 | x |
| 2023-12-31 | $0.86 | $24.40 | x |
| 2024-12-31 | $0.87 | $24.40 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Ascentage Pharma Group International utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -153.46%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -41.34%
- • Asset Turnover: 0.37x
- • Equity Multiplier: 9.91x
- Recent ROE (-153.46%) is above the historical average (-245.70%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 0.00% | -1406.53% | 0.01x | 0.00x | $-106.38 Million |
| 2017 | 0.00% | -1872.85% | 0.01x | 0.00x | $-105.33 Million |
| 2018 | 0.00% | -5072.82% | 0.01x | 0.00x | $-244.15 Million |
| 2019 | -166.28% | -10202.67% | 0.01x | 1.35x | $-1.57 Billion |
| 2020 | -80.04% | -5442.62% | 0.01x | 2.04x | $-762.27 Million |
| 2021 | -63.37% | -2803.38% | 0.01x | 2.38x | $-905.90 Million |
| 2022 | -216.05% | -421.02% | 0.07x | 6.93x | $-923.79 Million |
| 2023 | -1532.08% | -416.98% | 0.09x | 41.39x | $-931.68 Million |
| 2024 | -153.46% | -41.34% | 0.37x | 9.91x | $-431.85 Million |
Industry Comparison
This section compares Ascentage Pharma Group International's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $57,799,710
- Average return on equity (ROE) among peers: -233.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Ascentage Pharma Group International (AAPG) | $675.91 Million | 0.00% | 3.51x | $2.25 Billion |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |